Company profile for InflaRx

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena an...
InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Germany
Address
Address
InflaRx N.V. Winzerlaer Str. 2 07745 Jena
Telephone
Telephone
+49 (0)3641 508 180
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/10/3184439/0/en/InflaRx-Reports-Positive-Phase-2a-Data-for-INF904-in-Hidradenitis-Suppurative-HS-and-Chronic-Spontaneous-Urticaria-CSU.html

GLOBENEWSWIRE
10 Nov 2025

https://www.globenewswire.com/news-release/2025/11/07/3183959/0/en/InflaRx-to-Announce-Topline-Data-from-Phase-2a-Clinical-Trial-of-INF904-in-Hidradenitis-Suppurativa-and-Chronic-Spontaneous-Urticaria.html

GLOBENEWSWIRE
07 Nov 2025

https://www.globenewswire.com/news-release/2025/10/21/3170072/0/en/InflaRx-Announces-Participation-in-the-Guggenheim-Securities-2nd-Annual-Healthcare-Innovation-Conference.html

GLOBENEWSWIRE
21 Oct 2025

https://www.globenewswire.com/news-release/2025/09/12/3149196/0/en/InflaRx-Regains-Compliance-with-Nasdaq-Minimum-Bid-Price-Requirement.html

GLOBENEWSWIRE
12 Sep 2025

https://www.globenewswire.com/news-release/2025/08/21/3137027/0/en/InflaRx-Announces-Participation-in-September-Investor-Conferences.html

GLOBENEWSWIRE
21 Aug 2025

https://www.globenewswire.com/news-release/2025/08/07/3129118/0/en/InflaRx-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Business-Update.html

GLOBENEWSWIRE
07 Aug 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty